ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD), which frequently leads to end-stage renal disease, currently has no specific drug therapies. Better understanding of its pathogenesis and recent clinical trials have led to more accurate diagnosis of the disease and its manifestations, as well as to promising new approaches to treatment.
- Copyright © 2014 The Cleveland Clinic Foundation. All Rights Reserved.
- William E. Braun, MD⇑
- Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Cleveland Clinic, one of seven US centers participating in the HALT-PKD collaborative study
- ADDRESS:
William E. Braun, MD, Department of Nephrology/and Hypertension, Q7, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: braunw{at}ccf.org
ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD), which frequently leads to end-stage renal disease, currently has no specific drug therapies. Better understanding of its pathogenesis and recent clinical trials have led to more accurate diagnosis of the disease and its manifestations, as well as to promising new approaches to treatment.
- Copyright © 2014 The Cleveland Clinic Foundation. All Rights Reserved.